Business Context and Reporting Period
This Form 8-K Current Report, dated October 15, 2024, details significant capital restructuring events for SANUWAVE Health, Inc. The filing covers events occurring between October 15 and October 18, 2024, including a reverse stock split, a private placement of equity, and amendments to existing debt agreements.
Key Financial Metrics and Capital Events
- Private Placement Proceeds: The Company raised approximately $10.3 million in gross proceeds from the sale of approximately 1.3 million shares of Common Stock at $8.25 per share.
- Debt Repayment: Proceeds are designated to repay the HealthTronics Note (original principal approx. $1.4 million) and satisfy obligations under the Consent and Limited Waiver.
- Reverse Stock Split: A 1-for-375 reverse stock split was implemented effective October 18, 2024.
- Debt-to-Equity Conversion: Approximately 3,989,456 shares were issued to exchange outstanding Future Advance Convertible Promissory Notes and Warrants. Notes were accelerated with 15% interest paid and converted at $15.00 per share.
- Liquidity Covenant: The Company must maintain at least $5.0 million in liquidity following these transactions to waive existing events of default under the Note and Warrant Purchase and Security Agreement (NWPSA).
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for a prior period. However, material changes in capital structure include:
- Capitalization: Significant increase in equity capital via the $10.3 million private placement.
- Share Count: Reduction in outstanding shares due to the 1-for-375 reverse split, partially offset by new issuances for the private placement and debt conversions.
- Debt Status: Conversion of multiple convertible notes and warrants into equity, reducing outstanding debt obligations.
- Default Status: Existing events of default under the NWPSA are currently being waived, contingent on meeting the $5.0 million liquidity threshold.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds will fund debt repayment (HealthTronics Note and NWPSA obligations) and working capital/general corporate purposes.
- Forbearance Period: Noteholders have agreed to forbear from exercising remedies regarding existing defaults until the earlier of a new default event or December 31, 2024.
- Issuance Restrictions: The Company is restricted from issuing new Common Stock or equivalents for 120 days post-closing and cannot file new registration statements for 90 days post-effective date of the resale registration.
- Risks: Failure to meet the $5.0 million liquidity covenant could result in the reinstatement of default events. The shares issued in the private placement are unregistered and subject to resale restrictions.
Investor Verification Checklist
- Verify the final post-transaction liquidity balance to confirm the $5.0 million minimum covenant is met.
- Confirm the effective date of the Registration Statement for the resale of the 1.3 million private placement shares (deadline: December 17, 2024).
- Review the full text of the Consent and Limited Waiver (Exhibit 10.1) for specific conditions precedent to the waiver of defaults.
- Monitor the December 31, 2024 deadline for the expiration of the forbearance agreement with note holders.
- Check for any fractional share cash settlements resulting from the 1-for-375 reverse stock split.